Perfluorinated compounds are related to breast cancer risk in greenlandic inuit: A case control study

Table 3 Serum POP related xenobiotic induced receptor transactivities in breast cancer patients and controls

Parameters	Cases				Controls				p value
	N (n)	median	95% CI	Min-max	N(n)	median	95% CI	Min-max
XER (RLU/μg protein)	31(31)	1.07	1.02; 1.10	0.80-1.30	115(110)	1.08	1.05; 1.11	0.54-1.34	0.69
% agonistic XER		38.7%				32.7%			0.54
% downregulated XER		9.7%				8.2%			0.79
XERcomp (RLU/μg protein)	31(31)	1.06	1.00; 1.08	0.79-1.27	115(110)	1.04	1.00; 1.05	0.55-1.26	0.58
% additive XERcomp		22.6%				19.1%			0.67
% antagonistic XERcomp		12.9%				12.7%			0.16
XAR (RLU/μg protein)	31(27)	1.02	0.97; 1.25	0.56-2.01	115(58)	0.91	0.86; 0.99	0.40-1.74	0.01
% agonistic XAR		18.5%				5.17%			0.02
% downregulated XAR		11.1%				24.1%			0.17
XARcomp (RLU/μg protein)	31(27)	0.69	0.61; 0.82	0.14-1.33	115(58)	0.72	0.68; 0.79	0.29-1.23	0.51
% additive XARcomp		3.7%				0.0			0.14
% antagonistic XARcomp		55. 6%				36.2%			0.59
AhR-TEQ (pg/L)	31(29)	292	285; 568	31.41-1442	115(113)	503	771; 1544	112-12757	<0.0001
AhR -TEQ (pg/g lipid)	31(29)	56.8	46.40; 90.80	8.97-231	115(113)	65.4	103; 219	11.50-2086	0.009

N: total number of subjects, n: number of subjects having information for the corresponding parameters.
XER and XAR: ER and AR transactivity of serum POP F1 extract alone, respectively. XERcomp and XARcomp: competitive receptor transactivity upon co-treatment with E2 or R1881, respectively. % agonistic XER and % XAR indicate a significant increase for the XER and XAR transactivity compared to the activity of the solvent control. % downregulated XER and % XAR indicated a significant decrease for the XER and XAR transactivity compared to the activity of the solvent control. % additive XERcomp and % additive XARcomp indicate a significant increase for the XERcomp and XARcomp transactivity compared to the activity of the E2-EC₄₀ and R1881-EC₅₀ solvent control, respectively. % antagonistic XERcomp and % antagonistic XARcomp indicate a significant decrease for the XERcomp and XARcomp transactivity compared to the activity of the E2-EC₄₀ and R1881-EC₅₀ solvent control, respectively. TEQ (TCDD equivalent): The TEQ value was calculated by interpolation of the AhR transactivity of serum extract to the TCDD dose-response curve using Sigmaplot program.

ISSN: 1476-069X